Abstract
Systemic lupus erythematosus (SLE) is the prototypical human, autoimmune disease and is characterized by immune dysregulation, production of autoantibodies, generation of circulating immune complexes, and activation of the complement system. SLE is notable for unpredictable exacerbations and remissions with a predilection for clinical involvement of joint, skin, kidney, brain, serosa, lung, heart, hematological system, and gastrointestinal tract (Wallace, The clinical presentation of systemic lupus erythematosus. In: Wallace D and Hahn B, Eds. Dubois’ Lupus Erythematosus, Lippincott Williams & Wilkins, Hagerstown, MD, 2006, pp. 621–628) (Table 19.1). The pathological hallmark of SLE is recurrent, widespread, and diverse vascular lesions including both inflammatory and thrombotic vasculopathy, the latter most often occurring in the setting of antiphospholipid antibodies. Cases related to the presentation and management of SLE are discussed (Belmont and Abramson, Arthritis and Rheumatism 39:9–23, 1996).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wallace D. The clinical presentation of systemic lupus erythematosus. In: Wallace D and Hahn B, Eds. Dubois’ Lupus Erythematosus, Lippincott Williams & Wilkins, Hagerstown, MD, 2006, pp. 621–628.
Belmont HM, Abramson S, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996, 39:9–23.
Betsias G, Ioannidis J, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report task for the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 2008, 67:195–205.
Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Int Med 2001, 135(4):248–257.
5. Mok, C. Therapeutic options for resistant Lupus Nephritis Semin. Arthritis Rheum 2006, 36:71–81.
6. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971–980.
7. Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006, 70(8):1403–1412.
8. Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006, 32(3):491–507.
Austin HA, Illei GG. Membranous lupus nephritis. Lupus 2005, 14(1):65–71.
Tincani A, Bazzani C, Zingarelli S, et al. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment. Semin Thromb Hemost 2008, 34(3):267–273.
Belmont HM. Catastrophic antiphospholipid syndrome. In: Khamashta M and Hughes G, Eds. Hughes Syndrome, 2006, pp. 152–161, Springer-Verlag London.
Crowther MA, Gisnberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133–1138.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Belmont, H.M. (2009). Immune-Mediated Rheumatic Diseases. In: Mahmoudi, M. (eds) Challenging Cases in Allergy and Immunology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-443-2_19
Download citation
DOI: https://doi.org/10.1007/978-1-60327-443-2_19
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-442-5
Online ISBN: 978-1-60327-443-2
eBook Packages: MedicineMedicine (R0)